PT35 Cost-Effectiveness Analysis of Nivolumab Versus Docetaxel for the Treatment of Advanced Nonsquamous NSCLC Including PD-L1 Testing in the United States

Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.2448
https://www.valueinhealthjournal.com/article/S1098-3015(24)02662-7/fulltext
Title : PT35 Cost-Effectiveness Analysis of Nivolumab Versus Docetaxel for the Treatment of Advanced Nonsquamous NSCLC Including PD-L1 Testing in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)02662-7&doi=10.1016/j.jval.2024.03.2448
First page :
Section Title :
Open access? : No
Section Order : 11286
Categories :
Tags :
Regions :
ViH Article Tags :